

SPUR THERAPEUTICS

**Two-year follow up of avigbogene parvec (FLT201) investigational
AAV gene therapy in adults with Gaucher disease type 1:
Results from GALILEO-1 and GALILEO-2**

Prof. Ida Vanessa D. Schwartz, MD, PhD.

Universidade Federal do Rio Grande do Sul, Hospital de Clinicas de Porto Alegre, Brazil

May 6, 2026

Disclosures – COI

Prof. Schwartz is the Brazilian PI for the Spur Therapeutics trials for Gaucher Disease.

Unmet needs in Gaucher Disease Type 1 (GD1) despite long-term treatment

Although ERT/SRT are effective in alleviating many aspects of GD1, there are still unmet needs

Prospective registry of 757 GD1 patients on ERT after 10 years ²		
Persistence after 10 years ERT	Non-Splenectomized	Splenectomized
Bone pain	43%	63%
Splenomegaly	38%	N/A
Thrombocytopenia	23%	1%
Hepatomegaly	14%	19%
Anemia	12%	9%
Bone crisis	7%	17%

- 60% failed to achieve at least one of 6 therapeutic goals after 4+ years of ERT¹
- Many continue to exhibit bone pain, organomegaly, and cytopenia after 10 years of ERT²
- 25% have physical limitations after 2 years of ERT, primarily due to bone disease³
- 80% of individuals with severe bone marrow burden showed no meaningful improvement after 8 years on ERT⁴
- 65% report fatigue despite treatment with ERT/SRT⁵

Avigbogene parvec (FLT201): Investigational AAV Gene Therapy for GD1



- Novel human liver-tropic AAV capsid (AAVS3)
- Transgene encoding GCCase85, a novel engineered variant of glucocerebrosidase
- GCCase85 has similar catalytic properties to human GCCase with increased enzymatic stability
 - 6-fold increase in human serum
 - 20-fold increase at lysosomal pH conditions
- Produces robust and sustained secretion of GCCase into the bloodstream
- No difference in predicted immunogenicity compared to velaglucerase alfa

Preclinical studies demonstrate:

- High and durable expression with favorable safety to 5 years
- Uptake in all disease-affected tissues
- Greater residence time in disease-affected tissues and organs compared to ERT
- Greater reduction of lyso-Gb1 versus ERT in all disease-affected tissues

Comper F, et al. Mol Ther. 2025.

GALILEO-1 / GALILEO-2 Overview

- **GALILEO-1:** First-in-human, open-label, multicenter study of FLT201
- **GALILEO-2:** Long-term follow-up study

Key Eligibility Criteria

- Adult \geq 18 years of age
- Diagnosis of GD1 with deficient GCase activity \leq 30% of normal in leukocytes at diagnosis
- \geq 2 years ERT/SRT
- Negative for antibodies to AAVS3

Primary Objective

- To assess the safety and tolerability of FLT201 in GD1 adults

Secondary / Exploratory Objectives

- Impact on spleen, liver, Hb and platelets
- Biomarkers
 - Lyso-Gb1
 - Chitotriosidase
 - CCL18
- Bone disease / fatigue / pain
- Impact on HRQoL
- Viral shedding
- Immune response

GALILEO-1 / GALILEO-2 Overview (cont.)

- Six participants have received a single low dose of FLT201: 4.5×10^{11} vg/kg
- Prophylactic immune management regimen began 3 weeks post-infusion*
- Four participants have discontinued their SoC (ERT/SRT)
 - Discontinued between 4 to 11 weeks post FLT201 infusion, all remain off ERT/SRT 2 years later
- Two participants remain on their SoC
 - Patient 5 – No durable enzyme expression or sustained improvements in lyso-Gb1; likely attributable to a heightened and less regulated immune response due to a confluence of contributing factors impacting transgene expression.
 - Patient 6 – No apparent GCase expression, detectable pre-existing AAVS3 NAbS at a titer below exclusion cut-off. GALILEO-3 will focus on patients with no detectable AAVS3 NAbS.
- All participants have enrolled in the long-term follow up study: GALILEO-2
- Patient follow-up ranges between 20 to 29 months after FLT201 dosing

*Prophylactic immune regimen consisted of oral steroids prednisolone/prednisone and/or oral tacrolimus


Baseline Characteristics

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
Age / Gender	35 / M	25 / M	24 / M	30 / F	24 / M	58 / F
Age at diagnosis	4	3	16	15	20	15
GBA1 Variant	p.Val433Leu; p.Asn409Ser	p.Asn409Ser; p.Leu483Pro	p.Gln112Valfs*32; p.Leu422fs; p.Leu483Pro; p.Ala495Pro	p.Asn409Ser; p.Leu483Pro	p.Asn409Ser; p.Leu29Alafs*18	p.Asn409Ser; p.Trp223Arg
Duration of SoC	4 years	22 years	9 years	14 years	4 years	24 years
Therapy at entry	ERT	SRT	SRT	ERT	SRT	SRT
Plasma GCase activity (µmol/L/h)	0.1	0.09	0.04	<0.1 [#]	0.5	<0.1
DBS Lyso-Gb1 (ng/mL)	102.9	10.3	383.3	72.2	257.0	52.6
Hemoglobin (g/dL)	15.1	15.2	14.5	13.3	17.0	12.6
Platelet count (x10 ³ /mL)	200	213	124	176	167	113
Spleen volume (MN)	1.82	1.32	2.67	2.01	8.09	5.78
Liver volume (MN)	1.12	1.06	0.80	0.77	1.10	0.92
Total BMB Score	7	7	11	11	13	7

[#] Below lower limit of quantification

Substantial increases in GCase activity observed

- Plasma GCase activity shows a substantial increase from baseline in the 4 patients who discontinued SoC
- A similar picture has been seen with GCase activity from Dried Blood Spots




Closed Symbols = Assay run by Lab 1; Open Symbols = Assay run by Lab 2

Substantial and durable reductions in lyso-Gb1 observed

Lyso-Gb1 is a reliable and validated biomarker for GD and highly correlated to disease severity and treatment response


- Lyso-Gb1 levels were maintained or reduced in all participants who discontinued their SoC
- Despite many years of treatment participants with elevated lyso-Gb1 had reductions as early as month 1 following FLT201 administration




Closed Symbols = Assay run by Lab 1; Open Symbols = Assay run by Lab 2

Sustained improvement or maintenance observed in hemoglobin and platelets after withdrawal of ERT and SRT

Hemoglobin and platelet levels have improved or remained in the normal range following administration of FLT201




Normal Hb [male] 13.8-17.2 g/dL Normal Hb [female] 11.0-15.5 g/dL




Normal platelet count 150-450 x 10³/µL

Patient 3 experienced a transient drop in hemoglobin due to a newly diagnosed iron deficiency. Once iron supplements were initiated, hemoglobin levels returned to normal.

Spleen and liver volumes have remained stable following administration of FLT201



- Patient 1
- Patient 2
- ▲ Patient 3
- ▼ Patient 4




Improvements in bone density


- Z-scores improved in all patients or were maintained in the normal range
- Meaningful gains occurred even in patients stable at baseline
- Improvements in Z-scores corresponds to substantial reductions in fracture risk in patients with Gaucher Disease¹

—●— Patient 1 —■— Patient 2
—▲— Patient 3 —◆— Patient 4

Left Femur - DEXA Z Scores Over Time



Lumbar Spine - DEXA Z Scores Over Time



FLT201 continues to be well-tolerated with favorable safety profile

- Infusions were well tolerated; with no infusion-related reactions
- ADRs were mild to moderate
- No dose-limiting toxicities
- 2 cases of ALT elevations above normal range ($\leq 2 \times \text{ULN}^*$) deemed related to therapy
 - These spontaneously resolved or were managed with immune therapy
- Transient anti-GCase antibodies in 2 patients
- ADRs related to immune management consistent with known profile

* Central lab values

Summary of ADRs (n \geq 2)	
Adverse Drug Reactions (ADR)	# events (# patients)
FLT201	
Elevated Alanine aminotransferase (ALT)	7 (6)
Fatigue	4 (3)
Activated partial thromboplastin time prolonged	2 (2)
Anti-GCase neutralizing antibodies	2 (2)
Prednisone	
Hyperglycemia	3 (3)
Weight increase	2 (2)
Panic attack	2 (1)
Tacrolimus	
Diarrhea	4 (4)

Adverse Drug Reactions with 2 or more reports

Conclusions

Safety

- FLT201 shows a favorable safety and tolerability profile with a single low dose of 4.5×10^{11} vg/kg
- Infusions were well tolerated
- ADRs were mild to moderate

Efficacy

- Clinical parameters and key biomarkers continue to show sustained improvement or maintenance for up to 2 years
- All participants who discontinued ERT/SRT remain off their background therapy

Conclusion

- FLT201 shows potential for meaningful improvements in clinical outcomes over the existing standard of care with a single infusion
- Continuous expression of GCase85, which is more stable than recombinant human GCase, ensures constant exposure to enzyme
- GALILEO-3 (Phase 3) is now active and enrolling participants

Acknowledgements

Study investigators

- USA – Dr. O Goker-Alpan, Dr. D Vats, Dr. G Maegawa
- Spain – Dr. P Giraldo, Dr J Villarubia, Dr. M Camprodon, Dr. X Solanich Moreno
- UK – Dr. R Sharma, Prof. D Hughes
- Brazil – Prof. I Schwartz
- Israel – Prof. H Baris-Feldman, Prof. S Revel-Vilk, Dr. N Ruhrman Shahar
- Paraguay – Dr. D Gonzalez
- Germany – Dr. N Muschol, Dr. E Mengel

The sponsor and authors thank the patients who participated in the GALILEO-1 and GALILEO-2 studies and their families, as well as those who support the Gaucher community